SLC16A1 and lymphoma: There are also other drugs available which are in clinical trial for targeting different cancer types such as- sirpiglenastat an antagonist of glutamine (phase I/II for solid tumors and NSCLC), AZD5965 inhibitor of MCT1 (phase II for solid tumors and lymphoma), IACS-010759 inhibitor of mitochondrial respiratory complex 1 (phase I for AML) (436).